Algorithm(s)
PDF algorithm(s) available at www.arupconsult.com.
Hyperaldosteronism Testing Algorithm
Clinical Background
Aldosteronism is a syndrome caused by excessive and inappropriate aldosterone production.
Epidemiology
- Prevalence - 5-15% of unselected hypertensive patients
- Age - 30-50 years
- Sex - F:M is 2:1
Etiologies
- Bilateral cortical nodular hyperplasia
- Aldosterone-producing tumor (Conn’s Syndrome)
- Adrenal carcinoma, rare in the general population
Pathophysiology
- Hypersecretion of aldosterone increases the renal distal tubular exchange of sodium for potassium and hydrogen
- Progressive depletion of potassium and hydrogen leads to hypokalemia and acidosis
- Excess sodium reabsorption leads to hypertension
- Classification
- Primary - excess aldosterone secretion by the adrenal glands
- Secondary - renin-mediated secretion
- Seen in congestive heart failure, nephritic syndrome, cirrhosis, renal artery hypertension, severe arteriolar nephrosclerosis, rare renin-secreting tumors
Clinical Presentation
- Constitutional - weakness, fatigue
- Renal - polyuria, proteinuria, renal failure
- Cardiac - hypertension, cardiac hypertrophy
- Edema - rarely exists
Treatment
- Often involves surgical excision of the tumor
- Aldosterone antagonists (spironolactone) may be successful therapy
Algorithm(s)
PDF algorithm(s) available at www.arupconsult.com.
Hyperaldosteronism Testing Algorithm
Diagnosis
Diagnosis
- Indications for testing
- Suggested by persistent hypokalemia and hypertension in patients with normal sodium intake, absence of edema and not currently receiving diuretics (from electrolyte testing)
- Hypokalemia - often severe; although patients may have normokalemia, particularly if already taking potassium-sparing diuretics
- Impaired urinary concentration
- Metabolic alkalosis
- Hypomagnesemia if hypokalemia is severe
- Hypernatremia is rare
- Patients may only present with hypertension and be normokalemic
- Laboratory testing
- Screening - upright Aldosterone: renin activity ratio, or upright aldosterone:direct renin ratio
- Confirmation
- Fludrocortisone suppression test
- Saline loading test
- Saline infusion test
- Captopril test
- Losartan suppression test
- Imaging studies
- Adrenal MRI or CT to screen for tumor
Algorithm(s)
PDF algorithm(s) available at www.arupconsult.com.
Hyperaldosteronism Testing Algorithm
Tests generally appear in the order most useful for common clinical situations
| Test name: Aldosterone/Renin Activity Ratio
|
| ARUP #: 0070073 |
| Methodology: Radioimmunoassay
|
| Use:
Diagnose primary hyperaldosteronism
Monitor effectiveness of treatment
|
| Limitations: |
| Follow-up:
|
| Test name: Electrolyte Panel
|
| ARUP #: 0020410 |
| Methodology: Ion-Selective Electrode/Enzymatic
|
| Use:
Monitor disease
|
| Limitations: |
| Follow-up:
|
Additional Tests Available
| Test name: Renin Activity
|
| ARUP #: 0070105 |
| Methodology: Radioimmunoassay
|
| Comments: |
| Test name: Electrolytes, Urine
|
| ARUP #: 0020498 |
| Methodology: Ion-Selective Electrode
|
| Comments: Monitor disease |
| Test name: Potassium, Plasma or Serum
|
| ARUP #: 0020002 |
| Methodology: Ion-Selective Electrode
|
| Comments: Monitor disease |
| Test name: Aldosterone, Urine
|
| ARUP #: 0070480 |
| Methodology: Radioimmunoassay
|
| Comments: |
| Test name: Aldosterone 60 Minute
|
| ARUP #: 0070017 |
| Methodology: Radioimmunoassay
|
| Comments: |
| Test name: Aldosterone 30 Minute
|
| ARUP #: 0070016 |
| Methodology: Radioimmunoassay
|
| Comments: |
References
General References
Calhoun DA. Aldosteronism and hypertension. Clin J Am Soc Nephrol.
2006;
1(
5):
1039-1045.
Gordon RD, Stowasser M. Primary aldosteronism: the case for screening. Nat Clin Pract Nephrol.
2007;
3(
11):
582-583.
Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens.
2004;
22(
5):
863-869.
Mantero F, Mattarello MJ, Albiger NM. Detecting and treating primary aldosteronism: primary aldosteronism. Exp Clin Endocrinol Diabetes.
2007;
115(
3):
171-174.
Mattsson C, Young WF Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol.
2006;
2(
4):
198-208.
Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F, Stewart PM. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab.
2005;
16(
3):
114-119.
Nishikawa T, Saito J, Omura M. Prevalence of primary aldosteronism: should we screen for primary aldosteronism before treating hypertensive patients with medication?. Endocr J.
2007;
54(
4):
487-495.
Nishizaka MK, Calhoun DA. Primary aldosteronism: diagnostic and therapeutic considerations. Curr Cardiol Rep.
2005;
7(
6):
412-417.
Padfield P. Primary aldosteronism: the case against screening. Nat Clin Pract Nephrol.
2007;
3(
11):
580-581.
Pimenta E, Calhoun DA. Resistant hypertension and aldosteronism. Curr Hypertens Rep.
2007;
9(
5):
353-359.
Schirpenbach C, Reincke M. Primary aldosteronism: current knowledge and controversies in Conn's syndrome. Nat Clin Pract Endocrinol Metab.
2007;
3(
3):
220-227.
Schirpenbach C, Reincke M. Screening for primary aldosteronism. Best Pract Res Clin Endocrinol Metab.
2006;
20(
3):
369-384.
Medical Reviewers
Lehman, Christopher M., M.D. Co-Medical Director, University Hospital Clinical Laboratory; Associate Professor, Clinical Pathology, University of Utah
Meikle, A. Wayne, M.D. Medical Director, RIA and Endocrinology at ARUP Laboratories; Professor of Internal Medicine and Pathology, University of Utah
Roberts, William L. , M.D., Ph.D. Medical Director, Automated Core Laboratory at ARUP Laboratories; Professor, Pathology, University of Utah
Comprehensive Review: July 2008
Last Update: July 2008